In short
FDA clearance answers whether a product can legally be sold. It does not answer whether a payer will reimburse it, whether it will hold up in a coverage dispute, or whether it will survive an audit or a lawsuit years after launch. Those questions are answered by clinical evidence — and the most practical way to build it is not a single expensive study, but an ongoing registry, ideally run under a shared protocol that spreads cost across multiple products. Companies that wait until a dispute happens to look for evidence are, in a real sense, uninsured. This applies to both newer categories with thin long-term data and established categories that already have some coverage — evidence has to be maintained continuously, not assumed permanent.
At a recent industry gathering spanning aesthetics, PRP, peptides, collagen, and wound care, one clinical researcher offered a framing that applies well beyond his own specialty:
Clinical evidence is success insurance.
Not a nice-to-have for marketing. Not a box to check for FDA. An insurance policy against the reimbursement disputes and legal exposure that tend to show up only after a product has already succeeded.
Success Increases Legal Risk — It Doesn’t Reduce It
The uncomfortable pattern he pointed to: in the U.S., the more successful a product becomes, the more likely it is to face scrutiny — litigation, audits, or government investigation. He referenced the Purdue/Sackler case and Medicare recoupment actions as illustrations of a broader point: when Medicare or the Department of Justice seeks repayment, they can seek the entire amount paid, not merely the profit a company earned.
FDA clearance, a track record of sales, or a physician’s personal experience with a product are not, on their own, a defense. What holds up is a prepared body of clinical evidence, documentation, and a legal and compliance framework built in advance — not assembled after a dispute has already started.
FDA Clearance Solves One Problem. Reimbursement Solves a Different One.
In payer disputes — before CMS, a payer’s medical policy team, or an Administrative Law Judge — the questions asked are not the same ones FDA asked. They tend to include: Is this product safe and effective for this specific use? Is it still considered investigational or experimental? Is there sufficient clinical research behind it? Is there evidence specific to this indication and this patient population?
| Pathway | What it actually solves |
|---|---|
| 510(k) clearance | Market access — whether the product can legally be sold |
| PDAC / HCPCS coding | The coding pathway — how the product is billed |
| Clinical evidence | Adoption, reimbursement defense, and long-term commercialization |
None of these three substitutes for the others. A company with clearance and a coding pathway but no clinical evidence strategy has solved two problems and left the third one entirely exposed.
Registries Are the Most Practical Way to Build Evidence Before You Need It
His core recommendation was straightforward: providers using a product should collect data on an ongoing basis, rather than scrambling for evidence only once a problem has already surfaced. A registry’s value compounds over time — it accumulates real-world safety data, efficacy and healing outcomes across different wound types and patient populations, material for future publication or meta-analysis, and a standing body of evidence a company can point to if it faces a CMS dispute, a DOJ inquiry, an Administrative Law Judge hearing, or litigation. It can also support future FDA applications or expanded indications.
He described the practical burden as light — a simple, single-page entry taking a few minutes per patient. [Note: this specific workflow detail should be confirmed directly with the source before being repeated as a firm claim — see the editorial note at the end of this article.]
Shared Protocols Can Lower the Cost of Building Evidence
One idea worth taking seriously: multiple products can be studied under a single master protocol, sharing a common standard-of-care control group instead of each manufacturer separately funding its own control arm. Once enough products have gone through this shared framework, the resulting data supports pooled analysis or meta-analysis — materially lowering the cost of generating evidence for any individual company.
For companies without the budget for an independent randomized controlled trial, the practical question is worth asking directly: can our product join an existing wound-care registry or master protocol, rather than starting a study from scratch?
An Established Category Isn’t Automatically a Safe One
PRP was offered as a useful case study. It already has data spanning more than 1,000 patients in wound care, along with some existing Medicare coverage and professional society recommendations. Even so, payers can still narrow or restrict that coverage if they determine the evidence doesn’t sufficiently support a specific use — which means PRP, too, needs continued registry work and publication.
The more accurate framing isn’t “PRP has no reimbursement and collagen does,” or the reverse. It’s that every category needs its own continuously maintained evidence, coverage rationale, and billing support — regardless of how established it already appears.
Newer Categories Carry Higher Long-Term Risk
Peptides drew a more cautious note: a large and growing market, paired with thin long-term safety data. The absence of reported adverse events today doesn’t rule out risks that might surface a decade from now. More permissive regulatory environments in some states may create commercial latitude, but they don’t eliminate product liability exposure. The practical implication for any newer category: start registry data collection from day one of commercial use, not once a safety question has already been raised.
Patient-Pay Research Is Possible — But Only Inside Real Guardrails
Several commercial research models came up in discussion: patients continuing to pay for treatment while agreeing to contribute data; reasonable compensation or discounts in exchange for participation; free initial treatments followed by paid ones; or a company providing the product while the patient covers other associated costs.
This is not a green light to design any patient-pay research structure freely. Every model discussed still requires IRB oversight, proper informed consent, a fair-market-value assessment, and legal compliance review. None of this should be treated as legal advice or implemented without qualified regulatory and legal counsel.
The evidence insurance stack
510(k) Clearance→PDAC / HCPCS Coding→Registry→Shared Protocol→Publication→Reimbursement Defense→Legal Defense
Market access clears the first bar. Everything after that is the insurance policy — and it has to be built before you need it, not after.
The underlying discipline here isn’t so different from the discipline behind structuring a business for AI visibility: in both cases, the knowledge that protects a company already exists somewhere — in provider experience, in early outcomes, in day-to-day use — and the risk isn’t that the evidence doesn’t exist. It’s that it hasn’t been captured, structured, and maintained before someone else asks for it.
Frequently Asked Questions
What does "clinical evidence is success insurance" mean?
It means clinical evidence functions less like a marketing asset and more like an insurance policy: it protects a product against reimbursement denials, payer audits, and legal claims that tend to appear only after a product becomes commercially successful. Companies that wait until a dispute arises to look for evidence are, in effect, uninsured.
Why doesn't FDA clearance guarantee reimbursement?
FDA clearance answers a market-access question: can this product legally be sold. Reimbursement disputes, which often play out before payers, CMS, or an Administrative Law Judge, ask different questions — whether the product is safe and effective for the specific use in question, whether it is still considered investigational, and whether there is sufficient clinical evidence for the specific indication and patient population. Regulatory clearance, coding, and clinical evidence solve three separate problems, and none of them substitutes for the others.
What is a clinical registry and why does it matter for emerging medical technologies?
A registry is an ongoing, structured collection of real-world data from providers using a product, rather than a one-time study. Its value includes real-world safety data, outcomes across different patient populations and use cases, material for future publication or meta-analysis, and a body of evidence a company can point to if it later faces a payer dispute, an audit, or litigation. Building this continuously is generally far less costly than trying to construct it retroactively under pressure.
What is a master protocol or shared control group, and how does it lower research costs?
A master protocol allows multiple products to be studied under one overarching research framework, sharing a common standard-of-care control group instead of each product funding its own independent control arm. Once several products have been studied this way, the resulting data can support pooled analysis or meta-analysis, which can meaningfully lower the cost of generating evidence for any single manufacturer.
Why can an established category like PRP still face reimbursement risk?
Even categories with a substantial evidence base and some existing Medicare coverage or society recommendations can still see that coverage narrowed or challenged if a payer decides the evidence is insufficient for a specific use. The more accurate framing isn't that an established category is "safe" and a newer one is "risky" — it's that every category needs its own continuously maintained evidence, coverage rationale, and billing support, regardless of how established it already is.
Why do newer categories like peptides carry higher long-term liability risk?
Newer categories often reach a large market before long-term safety data exists. The absence of reported adverse events today doesn't rule out risks that surface years later, and more permissive regulatory environments in some jurisdictions don't eliminate product liability exposure. This is why newer categories generally benefit from starting registry data collection from the first day of commercial use rather than waiting until a safety question arises.
Related to this thinking
Evidence is one readiness area — not the whole path
Registries, master protocols, and a publication strategy build the evidence layer described above. But evidence on its own doesn’t move a Value Analysis Committee, a distributor, or a GPO to a purchase decision — each of them is asking a different question, and each needs that evidence translated into their own terms.
The Alzaro MedTech Market Access OS treats Evidence Readiness as one of five readiness areas — alongside Market, Regulatory, Commercial, and AI/GEO Visibility readiness — so a company can see not just whether its evidence is defensible, but whether it’s actually reaching the people who decide.